Advances in the Research of the Immunological Function of LAG-3 and Its Antibody Drugs

TIAN Baojun¹^,2, YU Hongyang², XU Mingbo², CAO Rongyue¹*, YANG Zhongfan²*

(¹School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China;²Beijing Shuanglu PharmaceuticalCo., Ltd., Beijing Engineering Research Center for Recombinant Proteins and Long-Acting Preparations, Beijing 100143, China)

Abstract:

LAG-3 (lymphocyte activation gene-3), also known as CD223, is a type of immune checkpoint receptor protein, which is primarily expressed in activated immune cells. LAG-3 can maintain immune homeostasis under physiological conditions and mediate the immune escape of tumor cells in the TME (tumor microenvironment). Therefore, LAG-3 can be used as a new target for tumor immunotherapy. LAG-3 blocking antibody can effectively relieve the tolerance caused by other immune checkpoint inhibitors, and has a better clinical effect in drug combination. At present, many LAG-3-related antibody drugs are in the development stage, some of which have entered the clinical stage. This paper systematically reviews the structure, expression, and function of LAG-3, as well as elaborates the clinical research progress and market situation of LAG-3-related antibody drugs.

CSTR: 32200.14.cjcb.2021.02.0026